Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

The study will recruit approximately 60 patients aged ≥18 years, with histologically proven
diagnosis of platinum-resistant relapsed high grade serous, high grade endometroid or clear
cell ovarian, fallopian tube or primary peritoneal carcinoma who have received at least 3
prior lines of therapy, and who do not carry a deleterious or suspected deleterious germline
BRCA mutation. All patients should have recurrent platinum resistant disease. The receipt of
prior antiangiogenic treatment (e.g. bevacizumab) is optional. If used, it can be in the
first line or recurrent setting. To be eligible to enter the study, all patients should have
measurable disease (as assessed by the Investigator).

There is no maximum duration for taking the study treatments (cediranib+olaparib). Patients
should continue on study treatments until objective radiological disease progression, as
defined by RECIST version 1.1 guidelines, or they meet other discontinuation criteria.
Following discontinuation of study treatment patients will be followed for disease
progression (if they have not already progressed), survival and post-progression anti cancer
therapies until the data cut-off for the primary analysis, approximately 8 months after
enrollment of the last patient.

Inclusion Criteria:

1. Ability and willingness to provide written informed consent, and to comply with the
requirements of the protocol

2. Females aged ≥18 years with previous histologically proven diagnosis of high grade
serous, high grade endometroid or clear cell ovarian cancer, fallopian tube or primary
peritoneal carcinoma

3. No evidence of deleterious or suspected deleterious germline mutation in BRCA1 or
BRCA2 genes

4. Recurrent platinum-resistant disease, defined as disease progression within 6 months
(182 days) of the last receipt of platinum-based chemotherapy

5. CT/MRI evidence of measurable disease as per RECIST 1.1 defined as at least one
lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10
mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) and
which is suitable for accurate repeated measurements

6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

7. Life expectancy ≥12 weeks

8. Prior receipt of antiangiogenic treatment, including but not limited to bevacizumab,
is optional. If used, it can be used in the first line or recurrent setting.

9. At least three prior lines of therapy for advanced ovarian cancer as defined in the
protocol

10. Confirmation of the availability of a tumor sample from the primary or recurrent
cancer must be provided

11. Patients must have adequate organ and bone marrow function

12. Adequately controlled blood pressure

13. Adequately controlled thyroid function, with no symptoms of thyroid dysfunction

14. Able to swallow and retain oral medications and without gastrointestinal illnesses
that would preclude absorption of cediranib or olaparib

15. Postmenopausal or evidence of non-childbearing status for women of childbearing
potential as confirmed by a negative urine or serum pregnancy test within 7 days prior
to start of IPs

Exclusion Criteria:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
staff and/or staff at the study site).

2. Previous enrollment in the present study.

3. Exposure to any IP during the last 4 weeks prior to enrollment.

4. Previous treatment with PARP inhibitor. For this study, BSI-201 (iniparib) is not
considered as PARPi

5. Recent cancer-directed therapies: Radiotherapy (RT) within 4 weeks, chemotherapy or
other systemic anti-cancer therapy within 4 weeks, or prior anti-angiogenic treatment
(e.g., bevacizumab) within 6 weeks prior to starting treatment

6. Cancer antigen-125 (CA-125) only disease without RECIST 1.1 measurable disease

7. Major surgical procedure within 2 weeks prior to starting treatment; patients must
have recovered from any effects of any major surgery and surgical wound should have
healed prior to starting treatment

8. Clinically significant signs and/or symptoms of bowel obstruction within 3 months
prior to starting treatment

9. History of intra-abdominal abscess within 3 months prior to starting treatment

10. History of GI perforation. Patients with a history of abdominal fistula will be
considered eligible if the fistula was surgically repaired, there has been no evidence
of fistula for at least 6 months prior to starting treatment, and patient is deemed to
be at low risk of recurrent fistula

11. Other malignancy within the last 5 years

12. Persisting ≥Grade 2 CTCAE toxicity (except alopecia and Grade 2 peripheral neuropathy)
from previous anti-cancer treatment(s)

13. Central nervous system metastases

14. Patients with any of the following: History of myocardial infarction within 6 months
prior to starting treatment; Unstable angina; Resting electrocardiogram (ECG) with
clinically significant abnormal findings; New York Heart Association functional
classification of III or IV

15. Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN) per
institutional guidelines, or <55%, if threshold for normal not otherwise specified by
institutional guidelines, for patients with the following risk factors: Prior
treatment with anthracyclines; Prior treatment with trastuzumab; Prior central
thoracic RT, including exposure of heart to therapeutic doses of ionizing RT; History
of myocardial infarction within 6-12 months prior to start of IPs; Prior history of
other significant impaired cardiac function

16. History of stroke or transient ischemic attack within 6 months

17. Uncontrolled intercurrent illness

18. Patients with myelodysplastic syndrome (MDS)/ treatment-related acute myeloid leukemia
(t-AML) or with features suggestive of MDS/AML

19. No prior allogenic bone marrow transplant or double umbilical cord blood
transplantation

20. Known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection
on antiviral treatment

21. Concomitant use of known strong or moderate CYP3A inhibitors

22. Concomitant use of known strong or moderate CYP3A inducers